Belatacept for Renal Allograft Recipients: A Compassionate Use Program.
Latest Information Update: 24 Nov 2021
Price :
$35 *
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Expanded access; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.
- 13 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jan 2010 Actual initiation date changed from Jan 2009 to Jan 2010 as reported by ClinicalTrials.gov.